CTOs on the Move


 
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.agios.com
  • 88 Sidney Street
    Cambridge, MA USA 02139
  • Phone: 617.649.8600

Executives

Name Title Contact Details

Similar Companies

Bioventus

Advancing orthobiologics to enhance the body’s ability to heal. Bioventus’ products are known for their safety, innovation, and effectiveness.

Takeda Pharmaceuticals

Takeda Pharmaceuticals is a Wilmette, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syntiron

Syntiron LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.